Table 2. Clinical characteristics of Non-DBA Patients.
| NON-DBA PATIENTS | SEX | AGE | TREATMENT | Hb (g/dL) | MCV (fL) | RBC (10^6/uL) | Reticulocytes (10^9/L) | DISEASE |
|---|---|---|---|---|---|---|---|---|
| 23 | F | 7 | NONE | 13.3 | 67.6 | 5.74 | 44.8 | Heterozygous for Beta Thalassemia |
| 24 | M | 4 | IRON | 12.0 | 80.5 | 4.16 | 69.9 | Iron deficiency anaemia |
| 25 | M | 1 | NONE | 12.2 | 70.6 | 4.96 | 55.7 | Heterozygosis for Hb S |
| 26 | M | 5 | NONE | 9.0 | 62.3 | 4.45 | 47 | Iron refractory anaemia |
| 27 | M | 9 | TRANSFUSION | 9.9 | 88.0 | 2.98 | 33.5 | Congenital dyserythropoietic anemia type II (CDA II) |
| 28 | M | 12 | NONE | 14.4 | 85.6 | 4.69 | 110.5 | Spherocytosis (Splenectomized) |
| 29 | M | 20 | NONE | 17.5 | 88.9 | 5.26 | 80.4 | Acquired erytrocytosis |
| 30 | M | 4 | NONE | 10.8 | 67.8 | 4.85 | 118.1 | Iron deficiency anaemia |
| 31 | F | 7 months | NONE | 8.2 | 76.3 | 3.19 | 64.9 | Homozygous for Beta thalassemia |
| 32 | M | 15 | CYCLOSPORIN, STEROIDS | 6.7 | 92.0 | 2.09 | 28.9 | Aplastic anaemia |
| 33 | F | 8 | STEROIDS | 9.9 | 85.4 | 3.4 | 44.7 | Aplastic anaemia |
| 34 | F | 14 | NONE | 9.1 | 85.0 | 3.19 | 56.4 | Congenital dyserythropoietic anemia type II (CDA II |
| 35 | M | 10 | NONE | 13.0 | 95.3 | 3.86 | 82.1 | Fanconi Anaemia |
| 36 | M | 10 | NONE | 13.0 | 77.1 | 4.97 | 77.3 | Lymphadenitis |
| 37 | M | 12 | NONE | 13.4 | 75.4 | 4.88 | N.D | Thrombocytopenia |
| 38 | M | 13 | MYCOPHENOLATE | 14.7 | 77.0 | 5.50 | 64.6 | Autoimmune lymphoproliferative syndrome (ALPS) |